Change of Retinal Vessel Diameter in Branch Retinal Vein Occlusion After Intravitreal Bevacizumab Injection
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Unoccluded retinal vessel diameter of Branch Retinal Vein Occlusion
研究概览
简要总结
The authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of Branch Retinal Vein Occlusion.
详细描述
Twenty five consecutive patients who had undergone intravitreal bevacizumab injection for Branch Retinal Vein Occlusion with macular edema were included in this study. All subjects were enrolled between April, 2012 and April, 2013 in the Department of Ophthalmology, Kyungpook National University Hospital.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Best-corrected visual acuity less than 20/40
- •Central subfield macular thickness (CSMT) 300 μm or greater on spectral-domain optical coherence tomography
排除标准
- •Patients with recurrent BRVO
- •History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation
- •Patients with diabetes or dyslipidemia
- •IOP ≥ 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy
- •High myopia (<-6 Diopters), high hyperopia (>6 Diopters) or a history of refractive surgeries
- •Co-existing retinal disease other than BRVO
- •Corneal diseases include ulcer, keratoconus and a history of corneal laceration
- •Cataract and other media opacities resulting in visual impairment or poor fundus images
结局指标
主要结局
Unoccluded retinal vessel diameter of Branch Retinal Vein Occlusion
时间窗: 0, 1, 3, and 6 months
To evaluate the change of unoccluded retinal vessel diameter in affected eye of Branch Retinal Vein Occlusion and unaffected fellow eye.
次要结局
未报告次要终点
研究者
Dong Ho Park
Clinical professor
Kyungpook National University Hospital